B of A Securities Maintains Buy on Avidity Biosciences, Raises Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
B of A Securities has maintained its Buy rating on Avidity Biosciences (NASDAQ:RNA) and raised the price target from $40 to $45.
June 13, 2024 | 4:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
B of A Securities has maintained its Buy rating on Avidity Biosciences and increased the price target from $40 to $45, indicating confidence in the company's future performance.
The raised price target and maintained Buy rating from a reputable analyst suggest positive sentiment and expected growth for Avidity Biosciences, likely leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100